Disc Medicine’s RALLY-IBD Trial Puts a Spotlight on Anemia Relief in IBD Patients
Disc Medicine, Inc. (IRON) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The RALLY-IBD study, officially titled “A Phase 2 Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of DISC-0974 in Participants With Inflammatory Bowel Disease and Anemia of Inflammation,” aims to treat anemia linked to IBD. It focuses on whether Disc Medicine, Inc. can safely improve blood counts and symptoms in this hard‑to‑treat group.
The trial tests DISC-0974, an injectable drug given under the skin. It is designed to improve anemia of inflammation in people with IBD, potentially reducing the need for transfusions or iron infusions and offering a more convenient option.
This is an interventional Phase 2 study with patients randomly assigned to active drug or placebo. It uses a parallel group design with both sides treated at the same time, and it is quadruple blinded so patients, doctors, trial staff, and outcome assessors do not know who gets DISC-0974.
Participants in the active arm receive 60 mg of DISC-0974 every 28 days for three doses, while the control arm gets placebo on the same schedule. The primary goal is treatment focused, looking at safety and early signs of benefit on anemia rather than long‑term outcomes.
The study was first submitted on January 22, 2026, marking the start of formal regulatory tracking and early site setup. The most recent update was filed on February 24, 2026, signaling that the protocol and recruiting status have been refreshed and the program is moving ahead.
The trial is currently listed as recruiting, so primary completion and overall completion dates are still in the future and not yet reported. Investors should assume data readouts are several quarters away, with any major efficacy signal likely to emerge only after all three doses and follow‑up are complete.
For IRON, the progress of RALLY-IBD adds an important mid‑stage asset targeting anemia in an inflammatory setting where treatment choices are limited. A clean safety profile and meaningful improvements in hemoglobin could support a higher valuation, as investors often pay premiums for differentiated anemia therapies with clear clinical demand.
Short term, the update mainly boosts confidence that management is executing on its pipeline and diversifying beyond classic iron‑disorder settings. Share price reactions may stay muted until concrete data arrive, but continued recruiting lowers program risk and may draw more specialist healthcare funds into the name.
In the wider space, anemia treatments are a crowded field, with large players active in chronic kidney disease, oncology, and GI‑related anemia. If DISC-0974 shows a strong profile in IBD, it could carve out a niche against IV iron products and older supportive therapies, though it will still need to differentiate on safety, convenience, and payer acceptance.
For now, the main takeaway is that IRON’s Phase 2 IBD anemia program is live, funded, and progressing through the recruiting phase. The study remains ongoing and updated, with further details available on the ClinicalTrials.gov portal.
To learn more about IRON’s potential, visit the Disc Medicine, Inc. drug pipeline page.
